+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 18Years +
All Genders
ID07255638

Observational Study of Avapritinib for Managing Indolent Systemic Mastocytosis with Uncontrolled Symptoms in Real-World Settings

Led by Blueprint Medicines Corporation · Updated on 2026-10-07

80

Participants Needed

12

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying the use of avapritinib, an oral drug targeting a specific KIT mutation, for people with Indolent Systemic Mastocytosis ISM in Germany. This observational study aims to understand how avapritinib works in real-world settings and to fill gaps in knowledge about the natural course and management of ISM, especially in patients whose symptoms are not well controlled by existing treatments. Participants will receive avapritinib as part of their regular treatment plan with their healthcare provider, following approved guidelines. The study will observe participants for up to 24 months while they take the medication as prescribed in routine care. Researchers will monitor changes in symptoms and quality of life using specific questionnaires and scores over time. During the study, participants will have assessments at the start and at various points up to 24 months, including questionnaires on quality of life and symptom control, blood tests measuring certain markers, and records of medical history and treatments. The main measure is the change in a quality of life questionnaire score at 6 months. Other outcomes include symptom scores, medication changes, hospital visits, and safety events related to ISM and avapritinib use.

CONDITIONS

Brief Title

A Non-Interventional Study in Participants With Indolent Systemic Mastocytosis (ISM) in Germany

Research Team

B

Blueprint Medicines, EU Contact

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here